Navigation Links
Leica M520 OH3

ProductsLeica M520 OH3
Company Leica Microsystems
Item Leica M520 OH3
Features True overhead design with superior reach and clearance. Complete auto-balance by a "one-button two-push" system. Precision mechanics for unmatched ease of intraoperative movement. Lightweight compact design for ease in transport, placement and storage. Six built-in electromagnetic brakes. Motorized inclination and tilt function. Robotic ability for tool tracking when combined with an IGS system. Two completely independent 300 Watt Xenon arc-illumination systems. Ergonomic, multifunctional handle as well as optional foot switch and mouth switch control. Full IGS compatible including the dual imaging system, the Leica DI C 500.
Description The Leica M520 OH3 is a smart system combining the best optical performance available on the market with an innovative and unique stand. The Leica M520 OH3 is the lightest, has the greatest range of movement and is the easiest system to move in the industry.
Info Leica Microsystems
Customer Service: (800) 526-0355
Web site: http://www.leica-microsystems.com

Related medicine products :

1. Leica DFC480
2. Leica DC480
3. Leica DC300 FX
4. Leica DFC300 F
5. Leica DFC350 F
6. Leica M500 MS3
7. Leica 2D
8. Leica D2D V3
9. Leica DI C500
10. Leica M500 OH3
11. Leica MS2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products:
(Date:5/4/2015)... (PRWEB) May 05, 2015 ... honors Irene Taylor , Volunteer Executive Director ... a 2015-2016 inductee into its VIP Woman of ... prestigious distinction for leadership in business. NAPW is ... women, boasting more than 700,000 members and over ...
(Date:5/4/2015)... Garden City, NY (PRWEB) May 05, 2015 ... honors Gloria M. Betancourt as a ... Year Circle. She is recognized with this prestigious distinction ... networking organization exclusively for professional women, boasting more than ... "I'm pleased to present Gloria with this important honor," ...
(Date:5/4/2015)... London, UK (PRWEB) May 04, 2015 ... to witness a 7.7% CAGR. Currently, the European and ... the world, while the North American probiotic market lags ... of local population. , The North American probiotic ... of over 58%), followed by Canada and Mexico. The ...
(Date:5/4/2015)... Monkton, MD (PRWEB) May 04, 2015 ... affecting families for generations. While it can have ... in disabling and catastrophic events. Hereditary Hemorrhagic Telangiectasia ... of blood vessels that lack normal capillary connections between ... nose can cause frequent, severe nosebleeds, but may also ...
(Date:5/4/2015)... Milton Hershey School® has named J. Anthony Graves, ... recognizing his commitment to pediatric cancer research and the ... students. , “Dr. Graves is a tremendous example of ... a top-notch education, a nurturing environment, and the opportunity ... ’85, president of MHS. “He is applying the values ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Milton Hershey School Names 2015 Alumnus of the Year 2
... Free from LTC Financial Partners, KIRKLAND, Wash., ... care,for an incapacitated parent or spouse, the impact ... estate or inheritance. And your loved,one,s daily needs ... *(PHOTO 72dpi: Send2Press.com/mediaboom/08-0227-JonasRoeser_72dpi.jpg), *(Photo Caption: LTC Senior ...
... Israel, Feb. 27 Shamir,Optical Industry Ltd. (Nasdaq: ... year end 2007 earnings results on Thursday, March 6, ... results at 9:00 A.M. EST,that morning., The conference ... To,listen live, please go to http://www.kcsa.com approximately ...
... 2008 -- A new study led by researchers at the ... diabetes who reported taking less insulin than prescribed had a ... complications than those who did not skip needed insulin shots. ... Care. , The study highlights the dangers of insulin restriction ...
... new article suggests that the United States government ... Cuba into a biomedical research institute dedicated to ... the open-access journal PLoS Neglected Tropical Diseases, Editor-in-Chief ... be in an optimal position to directly address ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") announced ... A. Cafaro, and Executive Vice,President and Chief Investment Officer, ... at the Citi 2008 Global Property CEO,Conference in Palm ... p.m.,Eastern Time., Those wishing to access the presentation ...
... Kansas City-based company connects, educates and entertains sports ... Sports enthusiasts have a new,online hotspot with Kansas ... have collaborated to produce AthletixNation.com, the premier,community for ... ultimate goal of AthletixNation.com is to have a ...
Cached Medicine News:Health News:Long Term Care Newsletter Helps Preserve Solvency & Sanity While Caring for Loved One 2Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2007 Earnings Results 2Health News:Joslin study finds restricting insulin doses increases mortality risk 2Health News:Joslin study finds restricting insulin doses increases mortality risk 3Health News:From detainee facility to health advocacy center: A new role for Guantanamo? 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)... May 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI ... terms of the agreement, Isis is eligible to receive ... immediate $100 million up-front payment and a $55 million ... 2 study in patients with compromised kidney function. Isis ...
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5